A new study by a Harvard dental professor may cast doubt on some claims that Merck's osteoporosis drug Fosamax caused some patients' jawbones to decay. The study shows that IV forms of the drug may have contributed to jaw disorders, but oral forms--which are far more commonly prescribed--actually reduced that risk. Report
Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product
Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.
